Kelly Logue
Bristol-Myers Squibb (United States)(US)Experimental Station(US)
Publications by Year
Research Areas
HIV Research and Treatment, HIV/AIDS drug development and treatment, HIV/AIDS Research and Interventions, Biochemical and Molecular Research, Quinazolinone synthesis and applications
Most-Cited Works
- → Inhibition of Clinically Relevant Mutant Variants of HIV-1 by Quinazolinone Non-Nucleoside Reverse Transcriptase Inhibitors(2000)300 cited
- → Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy(2001)239 cited
- → Nonsymmetric P2/P2‘ Cyclic Urea HIV Protease Inhibitors. Structure−Activity Relationship, Bioavailability, and Resistance Profile of Monoindazole-Substituted P2 Analogues(1998)50 cited
- → Synthesis, antiviral activity and pharmacokinetics of P1/P1′ substituted 3-aminoindazole cyclic urea HIV protease inhibitors(2003)33 cited
- → Improved P1/P1‘ Substituents for Cyclic Urea Based HIV-1 Protease Inhibitors: Synthesis, Structure−Activity Relationship, and X-ray Crystal Structure Analysis(1997)27 cited
- → DPC 681 and DPC 684: Potent, Selective Inhibitors of Human Immunodeficiency Virus Protease Active against Clinically Relevant Mutant Variants(2001)12 cited